Green Thumb Industries Expands Independent Governance with Appointment of Swati Mylavarapu to Board of Directors

CHICAGO and VANCOUVER, British Columbia, April 07, 2021 (GLOBE NEWSWIRE) — Green Thumb Industries Inc. (Green Thumb) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of Rise™ Dispensaries, today announced that Swati Mylavarapu has joined its Board of Directors and will serve on the Compensation Committee.

Mylavarapu brings nearly a decade of experience investing, advising and building mission-driven technology companies. Since 2017, Mylavarapu has served as Founder and Managing Partner of Incite.org, a hybrid incubator and investment fund that combines venture capital, philanthropy, and civic advocacy to accelerate bold ideas and solve some of the world’s most pressing challenges. She was an investment partner at venture capital firm Kleiner Perkins Caufield & Byers from 2015 to 2017. Prior to that, Mylavarapu built the early international efforts for the financial services and digital payments company Square.   She also served as National Investment Chair for Pete Buttigieg’s 2019-2020 Presidential bid.

“Swati’s impressive background, stellar credentials and combined experience in technology, innovation, social impact and philanthropy bring a unique and invaluable perspective to our board,” said Green Thumb Founder and Chief Executive Officer Ben Kovler. “We could not be more excited to add her voice and skillsets to the team.”

“I am honored to join the Board of Directors of Green Thumb, whose mission, values and executive team I deeply respect,” said Mylavarapu. “I look forward to making a positive impact for a company that aligns with my principles and prioritizes being good corporate citizens by giving back to communities, creating opportunity and jobs, and advocating for social change.”

Mylavarapu is a trustee for the Rhodes Trust, an educational charity that supports exceptional students from around the world to study at the University of Oxford. She is also a board member for Vote.org, which uses technology to simplify political engagement, increase voter turnout, and strengthen American democracy. She previously served on the boards of B Lab and Paid Leave for the U.S.

She has a Master of Philosophy in Economic and Social History from the University of Oxford and a Bachelor of Arts degree from Harvard. She is a Rhodes Scholar, a Truman Scholar and a member of Phi Beta Kappa.

Mylavarapu joins the following non-executive Green Thumb board directors:

Wendy Berger: Principal, WBS Equities, LLC., which specializes in ground-up construction, renovation, development, sale lease back transactions and acquisitions.

William Gruver: Senior Fellow at the Open Discourse Coalition, Professor Emeritus at Bucknell University, former Chief Administrative Officer of the Equities Division of Goldman Sachs, decorated Navy veteran and experienced Audit Committee chair. Serves on the Audit Committee of Private Client Bank and Finance Committee of the Lee Health System Foundation.

Wes Moore: CEO of Robinhood, New York’s largest poverty-fighting organization, best-selling author and decorated Army combat veteran. Serves on the boards of IAC/Interactive Corp. and Under Amour.

Glen Senk: Chairman and CEO of Front Row Partners, Advisory Director to Berkshire Partners and former CEO of Urban Outfitters. Serves on the boards of Aritzia and Boden.

About Green Thumb Industries:

Green Thumb Industries Inc. (“Green Thumb”), a national cannabis consumer packaged goods company and retailer, promotes well-being through the power of cannabis while giving back to the communities in which it serves. Green Thumb manufactures and distributes a portfolio of branded cannabis products including Beboe, Dogwalkers, Dr. Solomon’s, incredibles, Rythm and The Feel Collection. The company also owns and operates rapidly growing national retail cannabis stores called Rise™. Headquartered in Chicago, Illinois, Green Thumb has 13 manufacturing facilities, licenses for 97 retail locations and operations across 12 U.S. markets. Established in 2014, Green Thumb employs over 2,400 people and serves thousands of patients and customers each year. The company was named a Best Workplace 2018 by Crain’s Chicago Business and MG Retailer magazine in 2018 and 2019. More information is available at GTIgrows.com.

Investor Contact:     Media Contact:
       
Jennifer Dooley     Linda Marsicano
Chief Strategy Officer     VP, Corporate Communications
[email protected]     [email protected]
310-622-8257     773-354-2004

Source: Green Thumb Industries

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/51069b34-dc09-48cd-8c41-ec51b3a8d70e



Jericho Energy Ventures Reports Q1-2021 Business Update: Growing Demand for its DCC™ Hydrogen Boiler Across Multiple Industries

NEWTOWN, Pa. and VANCOUVER, British Columbia, April 07, 2021 (GLOBE NEWSWIRE) — Approximately six weeks following its acquisition of Hydrogen Technologies Inc (“HTI”), Jericho Energy Ventures (TSXV: JEV; Frankfurt: JLM0; OTC: JROOF) (“Jericho” or “JEV” or the “Company”) is pleased to provide shareholders with an update about the substantial progress and increasing demand for HTI’s patented zero-emissions, hydrogen-based, cleanH2steam Dynamic Combustion Chamber™ (DCC™) boiler.   

The Company has had ongoing discussions with a roster of potential customers that are large consumers of heat and steam for space heat, hot water, high-quality process steam and high-pressure steam for Combined Heat & Power applications. Steam intensive industries that aim to decarbonize their processes are inquiring about the DCC™, including companies focused on basic Chemicals and Petrochemicals as well as Food and Beverage processing. As more corporations sign on to become Net-Zero, analyzing thermal energy requirements becomes an immediate focus for achieving their objectives. The DCC™ solution allows our customers to fast track their emission reduction targets.  

The Food and Beverage industry, in particular, is highly focused on delivering consumers with low Carbon Content products introducing Carbon Labels showing a product’s lifetime carbon footprint. The growing use of so-called Carbon Labels comes as consumers, investors and regulators are increasingly interested in emissions amid rising concern about global warming. Over 57% of the food and beverage processing industries’ carbon emissions come from high utilization of steam for sterilization, disinfecting, reducing microbiological risks in addition to cooking, curing and drying. Reducing their emissions, means reducing their reliance on emissions-based boilers.

The second source of inbound demand has largely come from customers and energy consultants focused on the Power and Utility markets, where the DCC™ can be utilized to create high-pressure steam for a turbine to run in a Combined Heat and Power plant setting. Hydrogen’s ability to be a store of energy and be separate from the DCC™ system allows customers to take advantage of favorable power pricing during off-peak hours or when renewable power sources generate excess power supply to produce the hydrogen input fuel – creating a favorable economic proposition.

Ryan Breen, Head of Corporate Strategy at JEV & HTI, commented, “Our growing customer pipeline is a testament to our unique zero-emissions hydrogen-based boiler. Intensifying efforts by large steam consuming corporations to achieve their Net-Zero goals, in addition to supportive public policy, provide strong tailwinds to our business fundamentals. We look forward to further educating the market about our new hydrogen-based solution and converting robust customer interest into repeatable sales.”

The latest global policy developments demonstrate the critical role clean hydrogen plays in the future energy and decarbonization plans of a rapidly expanding roster of nations and Fortune 500 companies.

HTI’s go-to-market strategy aims at decarbonizing the nearly $30 billion Commercial & Industrial heating sectors with clean Steam and the Company recently announced a manufacturing partner for its DCC™ boilers as the first step in scaling up the business to meet the ever evolving demand for its zero emission hydrogen-based boiler solution.

In addition, as previously announced, JEV had engaged Hybrid Financial Ltd. (“Hybrid”) to provide marketing services to the Company. Hybrid, located in Toronto, Ontario and managed by Steven Marshall, has been retained to expand market and brand awareness for JEV and to broaden the Company’s reach within the investment community. Hybrid is in the business of providing marketing and investor communication services. Hybrid has been engaged by JEV for an initial period of six months and will be paid a monthly fee of CAD$15,000 plus applicable taxes.   With the exception of the agreement to provide the foregoing services, JEV does not have any relationship with Hybrid. Hybrid does not hold, directly or indirectly, any securities of JEV or a right to acquire such securities.

JEV had also engaged Winning Media (“WM”) to provide strategic digital media services, marketing, and data analytics services (the “Services”). WM, located in Houston, Texas and managed by Ty Hoffer and is in the business of providing copywriting and design services. The Company has agreed to pay USD$150,000 in consideration for the Services to be provided for a 1-month term and is renewable at the Company’s option. With the exception of the agreement to provide the Services, JEV does not have any relationship with WM. WM does not hold, directly or indirectly, any securities of JEV or a right to acquire such securities.

About Jericho Energy Ventures

Jericho Energy Ventures (https://jerichoenergyventures.com) is focused on advancing the low-carbon energy transition with investments in hydrogen technologies, energy storage, carbon capture and new energy systems.

CONTACT:

Adam Rabiner
Director of IR
Jericho Energy Ventures
604.343.4534
[email protected]

This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only Jericho’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Jericho’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Although Jericho believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. Forward-looking information and statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information and statements which include, but are not limited to: the effects of and risks associated with the ongoing COVID-19 pandemic, the impact of general economic conditions, industry conditions and current and future commodity prices including sustained low oil prices, significant and ongoing stock market volatility, currency and interest rates, governmental regulation of the oil and gas industry, including environmental regulation; geological, technical and drilling problems; unanticipated operating events; competition for and/or inability to retain drilling rigs and other services; the availability of capital on acceptable terms; the need to obtain required approvals from regulatory authorities; liabilities inherent in oil and gas exploration, development and production operations; and the other factors described in our public filings available at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.The forward-looking information and forward-looking statements contained in this news release are made as of the date of this news release, and Jericho does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



Liquidia Corporation To Present At The 20th Annual Needham Virtual Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., April 07, 2021 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Damian deGoa, Chief Executive Officer of Liquidia, will provide an overview and update on the company’s business during a fireside chat session at the 20th Annual Needham Virtual Healthcare Conference.

The presentation will take place on Wednesday, April 14, 2021, from 1:30 to 2:10 p.m. Eastern Standard Time and can be accessed via a live webcast on the Liquidia website at https://liquidia.com/investors/events-and-presentations. An archived, recorded version of the presentation can be accessed for 90 days following the event.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies is developing two product candidates: LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of PAH, and LIQ865, an injectable, sustained-release formulation of bupivacaine for the management of local post-operative pain for three to five days after a procedure. Liquidia PAH provides the commercialization for rare disease pharmaceutical products, such as Treprostinil Injection. Liquidia Corporation is headquartered in Research Triangle Park, NC. For more information, please visit www.liquidia.com.

Contact Information

Investors & Media:

Jason Adair
Vice President, Corporate Development and Strategy
919.328.4400
[email protected]



Oyster Consulting Hires Jeff Gearhart, Expands Trading and Markets Team

Gearhart to focus on growing Trading and Markets services

RICHMOND, Va., April 07, 2021 (GLOBE NEWSWIRE) — Oyster Consulting, a financial services consulting firm, announced today that Jeff Gearhart has joined the Strategic Planning and Execution team to focus on growing the firm’s Trading and Markets services.

With over 30 years in the financial services industry, Jeff Gearhart’s leadership experience in Capital Markets and broker-dealer businesses bolsters Oyster’s knowledge base and expertise. Having held senior positions, including business line COO, CFO, business development and product management roles, Jeff knows the issues and challenges facing Oyster’s clients and can partner with them through the decision making and execution process.

Prior to joining Oyster, Jeff served as Managing Director for BNY Mellon in the capital markets and securities finance businesses. In addition to serving as the Head of the Broker-Dealer for BNY Mellon Capital Markets, LLC, he led numerous initiatives to improve trading, sales processes, operations processes and operating margins, expand products and services, and mitigate risk.
  
“Having Jeff on the team solidifies Oyster’s expansion into the Institutional and Capital Markets client segment. His experience also strengthens Oyster’s Clearing Advisory, Strategic Planning and Conversion services. We are very proud and excited to have him on board,” said Pete Bowman, Managing Director of Oyster’s Strategic Planning and Execution team.  

“I am excited to join the team of professionals at Oyster Consulting,” said Gearhart. “I look forward to leveraging our combined experience and knowledge to partner with our clients and help them grow their business.”  

ABOUT OYSTER CONSULTING


Oyster Consulting
provides consulting, outsourcing and software solutions to the financial services industry. Our experienced industry practitioners add more value than career consultants and help us approach each client with unbiased information and practical solutions to meet their challenges.

CONTACT
Pete Bowman
Managing Director, Strategic Planning & Execution Team, Oyster Consulting LLC
(804) 965-5400
[email protected]
www.oysterllc.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a0e1d181-3812-4c0b-bcfb-ed0862721c47

 



The Simply Good Foods Company Reports Fiscal Second Quarter 2021 Financial Results; Provides Full Fiscal Year 2021 Outlook

DENVER, April 07, 2021 (GLOBE NEWSWIRE) — The Simply Good Foods Company (Nasdaq: SMPL) (“Simply Good Foods,” or the “Company”), a developer, marketer and seller of branded nutritional foods and snacking products, today reported financial results for the thirteen and twenty-six weeks ended February 27, 2021. The Company’s fiscal second quarter 2021 and year-to-date period results include Quest results for the full period. The Company’s fiscal second quarter 2020 results include thirteen-weeks of Quest and about twenty-three weeks for the year-to-date period.

Highlights:

(1)

  • Net sales increased 1.5% driven by strong e-commerce and Quest performance
  • Net income of $19.1 million versus $10.7 million
  • Earnings per diluted share (“EPS”) of $0.19 versus $0.11
  • Adjusted Diluted EPS

    (3)

    of $0.25 versus $0.23
  • Adjusted EBITDA

    (2)

    increased 2.2% to $42.6 million
  • Provides full fiscal year 2021 outlook:

    • Net Sales expected to be in the $930-940 million range
    • Adjusted EBITDA

      (2)

      expected to be in the $180-185 million range

“In the second quarter we executed well against our initiatives driving sales and earnings growth in a challenging operating environment due to continued reduced consumer mobility related to COVID-19,” said Joseph E. Scalzo, President and Chief Executive Officer of Simply Good Foods. “Retail takeaway in measured channels was slightly better than the last quarter and our e-commerce momentum continued. Our earnings growth and strong cash flow have provided us with flexibility to invest in our business and deleverage. Our fiscal third quarter is off to a good start and we’re positioned well to deliver on our plans over the remainder of the fiscal year.”

Fiscal Second Quarter 2021 Results

Net sales increased $3.5 million, or 1.5%, to $230.6 million. The core North America and international net sales increase contributed 1.0% and 1.7%, respectively, to total Company growth and the SimplyProtein® brand divestiture and the European business exit were a combined 1.2% headwind. As expected, trade promotion expense was greater than last year supporting higher levels of in-store merchandising and display. Additionally, as discussed last quarter, second quarter net sales were affected by the timing of shipments related to the seasonal inventory build by certain retailers that occurred in the first quarter.

Total Simply Good Foods retail takeaway for the thirteen weeks ending February 28, 2021, increased 1.7% in the U.S. measured channels of IRI MULO + Convenience Stores, and outpaced the category. The Company estimates that its U.S. retail takeaway in measured and unmeasured channels increased mid-single-digits, on a percentage basis versus last year, driven by solid Quest measured channel performance and about a combined 60% year-over-year increase within the e-commerce channel for the Atkins® and Quest® brands.

Gross profit was $90.3 million for the second quarter of fiscal 2021, an increase of $4.9 million. Gross margin was 39.1%, an increase of 150 basis points versus last year. The year ago period was negatively affected by a non-cash $5.1 million inventory purchase accounting step-up adjustment related to the Quest acquisition that was a 220 basis point headwind in the second quarter of fiscal 2020. In the second quarter of fiscal 2021, gross profit growth was affected by higher trade promotion expense.

In the second quarter of fiscal 2021 the Company reported net income of $19.1 million compared to net income of $10.7 million for the comparable period of 2020. The increase in net income was primarily due to lower transaction and integrations costs related to the Quest acquisition. Selling and marketing expense declined $0.9 million, due to lower selling costs as a result of the Quest integration. Total Company second quarter of fiscal 2021 marketing and advertising expense was about the same as the year ago period due primarily to the decline of investments in the SimplyProtein brand. In the second quarter of fiscal 2021, core North America and international marketing and advertising expense increased 8.0%. For the full year, the Company continues to anticipate that marketing and advertising expense related to its core businesses will increase at least in-line with organic sales growth. General and administrative expenses declined $1.5 million as cost control measures and Quest acquisition synergies more than offset an increase in incentive compensation.

Adjusted EBITDA(2), a non-GAAP financial measure used by the Company that makes certain adjustments to net income calculated under GAAP, increased 2.2% to $42.6 million.

Interest expense was $8.0 million, a decline of $2.6 million versus the second quarter of fiscal 2020, due to the repayment of term loan debt.

In the second quarter of fiscal 2021, the Company reported Diluted EPS of $0.19 versus $0.11 in the year ago period. Adjusted Diluted EPS(3), a non-GAAP financial measure used by the Company that makes certain adjustments to Diluted EPS calculated under GAAP, was $0.25 versus $0.23 in the year ago period.

Year-to-Date Second Quarter 2021 Results Financial Highlights vs. Year-to-Date Second Quarter 2020

  • Net sales increased 21.8%, or $82.5 million, to $461.8 million
  • Gross profit margin of 39.9%, an increase of 100 basis points
  • Net income increased $35.8 million to $41.6 million
  • Adjusted EBITDA

    (2)

    increased 24.2%, to $91.3 million
  • Earnings per diluted share (“EPS”) of $0.41, an increase of $0.35 per fully diluted share
  • Adjusted Diluted EPS of $0.54, an increase of $0.09 per fully diluted share

Net sales increased $82.5 million, or 21.8%, to $461.8 million. The core North America and international net sales increase contributed 20.9% and 2.3%, respectively, to total Company growth and the SimplyProtein® brand divestiture and the European business exit were a 1.4% headwind.

Gross profit was $184.3 million for the twenty-six weeks ending February 27, 2021, an increase of $36.7 million or 24.9%. The increase in gross profit was driven by the Quest acquisition. Gross margin was 39.9% in the first half of fiscal 2021, an increase of 100 basis points. Gross profit in the prior year was negatively affected by a non-cash $7.5 million inventory purchase accounting step-up adjustment related to the Quest acquisition. This non-cash inventory purchase accounting step-up was a 200 basis point headwind in the first half of fiscal 2020. Year-to-date second quarter fiscal 2021 gross profit growth was affected by the previously mentioned higher trade promotion expense as well as the effect of slightly unfavorable brand, channel and product mix.

Net income was $41.6 million compared to net income of $5.9 million for the comparable period of 2020. The increase was driven by sales and gross profit growth and a $37.5 million decline of costs related to the Quest acquisition and integration. Additionally, the increase in gross profit was offset by:

  • a 12.9% increase in selling and marketing expenses primarily due to the inclusion of Quest;
  • a $5.7 million increase in general and administrative expenses to $52.0 million as a result of the inclusion of Quest. Integration synergies more than offset higher incentive compensation.

Adjusted EBITDA(2), a non-GAAP financial measure used by the Company that makes certain adjustments to net income calculated under GAAP, increased 24.2% to $91.3 million.

For the first half of fiscal 2021, the Company reported Diluted EPS of $0.41, an increase of $0.35, versus $0.06 in the year ago period. Adjusted Diluted EPS(3), a non-GAAP financial measure used by the Company that makes certain adjustments to diluted earnings per share calculated under GAAP, was $0.54 versus $0.45 in the year ago period. Weighted average total diluted shares outstanding were approximately 100.6 million versus approximately 97.6 million in the year ago period.

Balance Sheet and Cash Flow

In the second quarter of fiscal 2021, combined cash flow from operations and the proceeds from the previously mentioned sale of the SimplyProtein brand, were about $45.6 million. In February 2021, the Company repaid $25.0 million of its term loan debt, and at the end of the second quarter the outstanding principal balance was $556.5 million. As of February 27, 2021, the Company had cash and cash equivalents of $91.3 million and a trailing twelve month Net Debt to Adjusted EBITDA ratio of 2.7x(4).

Outlook

“Our business continues to perform well despite the significant effects over the last year due to reduced consumer mobility related to COVID-19. In the second half of the year, we anticipate overall marketplace trends will improve due to easier year ago comparisons, improving shopping trips in measured channels and an increase in consumer mobility. We have a portfolio of brands aligned with consumer mega-trends of both health and wellness, convenience and on-the-go nutrition. Over the remainder of the year we have solid plans in place for both the Atkins and Quest brands, including, innovation, advertising and in-store merchandising and display that we anticipate will drive solid sales and earnings growth.”

Assuming consumer mobility in the United States remains at current levels and broad lockdowns are not reimposed, the Company anticipates full year fiscal 2021 net sales of $930-940 million and Adjusted EBITDA(2,5) of $180-185 million. The divestiture of SimplyProtein® and the European business exit is about a combined 1.5% headwind to full year fiscal 2021 net sales growth versus a previous estimate of 2%. Given year-to-date gross margin performance, and reinstated trade promotion expense related to in-store merchandising and display in the second half of the year, the Company expects full year gross margin, apart from the inventory purchase accounting step-up in the year ago period, to be slightly lower compared to fiscal 2020. The Company’s previous outlook indicated full year gross margin would be about the same as fiscal 2020. Additionally, due to solid cost control and acquisition synergies, the Company continues to anticipate Adjusted EBITDA margin expansion in fiscal 2021.

The Company anticipates 2021 Adjusted Diluted EPS(3,5) to be in the range of $1.07 to $1.11 versus $0.91 in 2020.

___________________________________
(1) All comparisons for the second quarter ended February 27, 2021 versus the second quarter ended February 29, 2020.
(2) Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) is a non-GAAP financial measure. Please refer to “Reconciliation of Adjusted EBITDA” in this press release for an explanation and reconciliation of this non-GAAP financial measure.
(3) Adjusted Diluted Earnings Per Share is a non-GAAP financial measure. The Company excludes acquisition related costs, such as business transaction costs, integration expense and depreciation and amortization expense in calculating Adjusted Diluted Earnings Per Share. Please refer to “Reconciliation of Adjusted Diluted Earnings Per Share” in this press release for an explanation and reconciliation of this non-GAAP financial measure.
(4) Net Debt to Adjusted EBITDA is a non-GAAP financial measure. Please refer to “Reconciliation of Net Debt to Adjusted EBITDA” in this press release for an explanation and reconciliation of this non-GAAP financial measure.
(5) The Company does not provide a forward-looking reconciliation of Adjusted Diluted Earnings Per Share to Earnings Per Share or Adjusted EBITDA to Net Income, the most directly comparable GAAP financial measures, expected for 2021, because we are unable to provide such a reconciliation without unreasonable effort due to the unavailability of reliable estimates for certain components of consolidated net income and the respective reconciliations, including the timing of and amount of integration costs and restructuring charges associated with the Quest acquisition, and the inherent difficulty of predicting what the changes in these components will be throughout the fiscal year. As these items may vary greatly between periods, we are unable to address the probable significance of the unavailable information, which could significantly affect our future financial results.

Conference Call and Webcast Information

The Company will host a conference call with members of the executive management team to discuss these results today, Wednesday, April 7, 2021 at 6:30 a.m. Mountain time (8:30 a.m. Eastern time). Investors interested in participating in the live call can dial 877-407-0792 from the U.S. and International callers can dial 201-689-8263.

In addition, the call and accompanying presentation slides will be broadcast live over the Internet hosted at the “Investor Relations” section of the Company’s website at http://www.thesimplygoodfoodscompany.com. A telephone replay will be available approximately two hours after the call concludes and will be available through Wednesday, April 21, 2021, by dialing 844-512-2921 from the U.S., or 412-317-6671 from international locations, and entering confirmation code 13717697.

About The Simply Good Foods Company

The Simply Good Foods Company (Nasdaq: SMPL), headquartered in Denver, Colorado, is a highly-focused food company with a product portfolio consisting primarily of nutrition bars, ready-to-drink shakes, sweet and salty snacks and confectionery products marketed under the Atkins®, Quest®, and Atkins Endulge® brand names. Simply Good Foods is poised to expand its wellness platform through innovation and organic growth along with investment opportunities in the snacking space and broader food category. Simply Good Foods aims to lead the nutritious snacking movement with trusted brands that offer a variety of convenient, innovative, great-tasting, better-for-you snacks and meal replacements. For more information, please refer to http://www.thesimplygoodfoodscompany.com.

Forward Looking Statements

Certain statements made herein are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by or include words such as “will”, “expect”, “intends” or other similar words, phrases or expressions. These forward-looking statements include the expected effects from the COVID-19 outbreak, statements regarding the integration of Quest, future plans for the Company, the estimated or anticipated future results and benefits of the Company’s future plans and operations, future capital structure, future opportunities for the Company, and other statements that are not historical facts. These statements are based on the current expectations of the Company’s management and are not predictions of actual performance. These statements are subject to a number of risks and uncertainties and the Company’s business and actual results may differ materially. These risks and uncertainties include, but are not limited to the effect of the COVID-19 outbreak on the Company’s business, suppliers (including its contract manufacturing and logistics suppliers), customers, consumers and employees along with disruptions or inefficiencies in the supply chain resulting from any effects of the COVID-19 outbreak; achieving the anticipated benefits of the Quest acquisition; difficulties and delays in achieving the synergies and cost savings in connection with the Quest acquisition; changes in the business environment in which the Company operates including general financial, economic, capital market, regulatory and political conditions affecting the Company and the industry in which the Company operates; changes in consumer preferences and purchasing habits; the Company’s ability to maintain adequate product inventory levels to timely supply customer orders; changes in taxes, tariffs, duties, governmental laws and regulations; the availability of or competition for other brands, assets or other opportunities for investment by the Company or to expand the Company’s business; competitive product and pricing activity; difficulties of managing growth profitably; the loss of one or more members of the Company’s or Quest’s management team; and other risk factors described from time to time in the Company’s Form 10-K, Form 10-Q, and Form 8-K reports (including all amendments to those reports) filed with the U.S. Securities and Exchange Commission from time to time. In addition, forward-looking statements provide the Company’s expectations, plans or forecasts of future events and views as of the date of this communication. Except as required by law, the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, and cautions investors not to place undue reliance on any such forward-looking statements. These forward-looking statements should not be relied upon as representing the Company’s assessments as of any date subsequent to the date of this communication.

Investor Contact

Mark Pogharian
Vice President, Investor Relations, Treasury and Business Development
The Simply Good Foods Company
(720) 768-2681
[email protected]



The Simply Good Foods Company and Subsidiaries

Condensed Consolidated Balance Sheets

(Unaudited, dollars in thousands, except share data)

    February 27, 2021   August 29, 2020
Assets        
Current assets:        
Cash and cash equivalents   $ 91,307     $ 95,847  
Accounts receivable, net   97,329     89,740  
Inventories   82,771     59,085  
Prepaid expenses   4,894     3,644  
Other current assets   12,833     11,947  
Total current assets   289,134     260,263  
         
Long-term assets:        
Property and equipment, net   11,092     11,850  
Intangible assets, net   1,146,039     1,158,768  
Goodwill   543,134     544,774  
Other long-term assets   32,119     32,790  
Total assets   $ 2,021,518     $ 2,008,445  
         
Liabilities and stockholders’ equity        
Current liabilities:        
Accounts payable   $ 43,585     $ 32,240  
Accrued interest   384     960  
Accrued expenses and other current liabilities   36,313     38,007  
Current maturities of long-term debt   278     271  
Total current liabilities   80,560     71,478  
         
Long-term liabilities:        
Long-term debt, less current maturities   548,884     596,879  
Deferred income taxes   92,536     84,352  
Other long-term liabilities   20,880     22,765  
Total liabilities   742,860     775,474  
See commitments and contingencies (Note 10)        
         
Stockholders’ equity:        
Preferred stock, $0.01 par value, 100,000,000 shares authorized, none issued        
Common stock, $0.01 par value, 600,000,000 shares authorized, 95,856,715 and 95,751,845 shares
issued at February 27, 2021 and August 29, 2020, respectively
  959     958  
Treasury stock, 98,234 and 98,234 shares at cost at February 27, 2021 and August 29, 2020,
respectively
  (2,145 )   (2,145 )
Additional paid-in-capital   1,098,375     1,094,507  
Retained earnings   182,150     140,530  
Accumulated other comprehensive loss   (681 )   (879 )
Total stockholders’ equity   1,278,658     1,232,971  
Total liabilities and stockholders’ equity   $ 2,021,518     $ 2,008,445  



The Simply Good Foods Company and Subsidiaries

Condensed Consolidated Statements of Operations and Comprehensive Income

(Unaudited, dollars in thousands, except share data)

    Thirteen Weeks Ended   Twenty-Six Weeks Ended
    February 27, 2021   February 29, 2020   February 27, 2021   February 29, 2020
Net sales   $ 230,607     $ 227,101     $ 461,759     $ 379,254  
Cost of goods sold   140,342     141,707     277,453     231,654  
Gross profit   90,265     85,394     184,306     147,600  
                 
Operating expenses:                
Selling and marketing   26,150     27,041     51,345     45,475  
General and administrative   26,562     28,103     51,977     46,248  
Depreciation and amortization   4,212     4,287     8,456     6,740  
Business transaction costs       694         26,853  
Total operating expenses   56,924     60,125     111,778     125,316  
                 
Income from operations   33,341     25,269     72,528     22,284  
                 
Other income (expense):                
Interest income       85     3     1,464  
Interest expense   (7,995 )   (10,589 )   (16,367 )   (15,558 )
Gain (loss) on foreign currency transactions   975     (194 )   984     (178 )
Other income   112     8     159     45  
Total other expense   (6,908 )   (10,690 )   (15,221 )   (14,227 )
                 
Income before income taxes   26,433     14,579     57,307     8,057  
Income tax expense   7,313     3,922     15,687     2,193  
Net income   $ 19,120     $ 10,657     $ 41,620     $ 5,864  
                 
Other comprehensive income:                
Foreign currency translation adjustments   243     (141 )   198     (141 )
Comprehensive income   $ 19,363     $ 10,516     $ 41,818     $ 5,723  
                 
Earnings per share from net income:                
Basic   $ 0.20     $ 0.11     $ 0.43     $ 0.06  
Diluted   $ 0.19     $ 0.11     $ 0.41     $ 0.06  
Weighted average shares outstanding:                
Basic   95,734,591     95,339,489     95,712,057     92,524,061  
Diluted   101,152,896     100,336,571     100,604,137     97,597,614  



The Simply Good Foods Company and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited, dollars in thousands)

    Twenty-Six Weeks Ended
    February 27, 2021   February 29, 2020
Operating activities        
Net income   $ 41,620     $ 5,864  
Adjustments to reconcile net income to net cash provided by (used in) operating activities:        
Depreciation and amortization   9,021     7,119  
Amortization of deferred financing costs and debt discount   2,108     1,569  
Stock compensation expense   3,594     3,795  
Unrealized loss (gain) on foreign currency transactions   (985 )   178  
Deferred income taxes   8,119     2,485  
Amortization of operating lease right-of-use asset   2,253     1,652  
Loss on operating lease right-of-use asset impairment   681      
Gain on lease termination   (154 )    
Other   216     789  
Changes in operating assets and liabilities, net of acquisition:        
Accounts receivable, net   (7,015 )   (19,062 )
Inventories   (24,502 )   768  
Prepaid expenses   (1,191 )   (873 )
Other current assets   (674 )   (5,808 )
Accounts payable   10,275     (2,953 )
Accrued interest   (577 )   175  
Accrued expenses and other current liabilities   (1,881 )   (8,760 )
Other assets and liabilities   (1,144 )   (1,824 )
Net cash provided by (used in) operating activities   39,764     (14,886 )
         
Investing activities        
Purchases of property and equipment   (449 )   (481 )
Issuance of note receivable       (1,250 )
Acquisition of business, net of cash acquired       (984,201 )
Proceeds from sale of business   5,800      
Investments in intangible assets   (114 )    
Net cash provided by (used in) investing activities   5,237     (985,932 )
         
Financing activities        
Proceeds from option exercises   527     931  
Tax payments related to issuance of restricted stock units   (252 )   (80 )
Payments on finance lease obligations   (168 )   (157 )
Principal payments of long-term debt   (50,000 )   (21,000 )
Proceeds from issuance of common stock       352,542  
Equity issuance costs       (3,323 )
Proceeds from issuance of long-term debt       460,000  
Deferred financing costs       (8,208 )
Net cash (used in) provided by financing activities   (49,893 )   780,705  
         
Cash and cash equivalents        
Net decrease in cash   (4,892 )   (220,113 )
Effect of exchange rate on cash   352     (113 )
Cash at beginning of period   95,847     266,341  
Cash and cash equivalents at end of period   $ 91,307     $ 46,115  






Reconciliation of Adjusted EBITDA


Adjusted EBITDA

. Adjusted EBITDA is a non-GAAP financial measure commonly used in our industry and should not be construed as an alternative to net (loss) income as an indicator of operating performance or as an alternative to cash flow provided by operating activities as a measure of liquidity (each as determined in accordance with GAAP). Simply Good Foods defines Adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) as net (loss) income before interest income, interest expense, income tax expense (benefit), depreciation and amortization with further adjustments to exclude the following items: business transaction costs, stock-based compensation expense, inventory step-up, integration costs, non-core legal costs, and other non-core expenses. The Company believes that the inclusion of these supplementary adjustments in presenting Adjusted EBITDA, when used in conjunction with net (loss) income, are appropriate to provide additional information to investors, reflects more accurately operating results of the on-going operations, enhances the overall understanding of past financial performance and future prospects and allows for greater transparency with respect to the key metrics the Company uses in its financial and operational decision making. The Company also believes that Adjusted EBITDA is frequently used by securities analysts, investors and other interested parties in the evaluation of companies in its industry. Adjusted EBITDA may not be comparable to other similarly titled captions of other companies due to differences in the non-GAAP calculation.

The following unaudited tables below provide a reconciliation of Adjusted EBITDA to its most directly comparable GAAP measure, which is net income, for the thirteen and twenty-six weeks ended February 27, 2021 and February 29, 2020:

(In thousands)

  Thirteen Weeks Ended   Twenty-Six Weeks Ended
  February 27, 2021   February 29, 2020   February 27, 2021   February 29, 2020
Net income   $ 19,120     $ 10,657     $ 41,620     $ 5,864  
Interest income       (85 )   (3 )   (1,464 )
Interest expense   7,995     10,589     16,367     15,558  
Income tax expense   7,313     3,922     15,687     2,193  
Depreciation and amortization   4,508     4,594     9,021     7,119  
EBITDA   38,936     29,677     82,692     29,270  
Business transaction costs       694         26,853  
Stock-based compensation expense   2,484     2,122     3,594     3,795  
Inventory step-up       5,085         7,522  
Integration of Quest   968     3,903     2,214     5,341  
Restructuring   1,267         3,786      
Non-core legal costs       76         555  
Other (1)   (1,011 )   174     (945 )   190  
Adjusted EBITDA   $ 42,644     $ 41,731     $ 91,341     $ 73,526  

(1) Other items consist principally of exchange impact of foreign currency transactions and other expenses.






Reconciliation of Adjusted Diluted Earnings Per Share


Adjusted Diluted Earnings per Share
. Adjusted Diluted Earnings per Share is a non-GAAP financial measure commonly used in our industry and should not be construed as an alternative to diluted earnings per share as an indicator of operating performance. Simply Good Foods defines Adjusted Diluted Earnings Per Share as diluted earnings per share before depreciation and amortization, business transaction costs, stock-based compensation expense, inventory step-up, integration costs, non-core legal costs, and other non-core expenses, on a theoretical tax effected basis of such adjustments. The tax effect of such adjustments to Adjusted Diluted Earnings Per Share is calculated by applying an overall assumed statutory tax rate to each gross adjustment as shown in the reconciliation to Adjusted EBITDA, as previously defined. The assumed statutory tax rate reflects a normalized effective tax rate estimated based on assumptions regarding the Company’s statutory and effective tax rate for each respective reporting period, including the current and deferred tax effects of each adjustment, and is adjusted for the effects of tax reform, if any. The Company consistently applies the overall assumed statutory tax rate to periods throughout each fiscal year and reassesses the overall assumed statutory rate on annual basis. The Company believes that the inclusion of these supplementary adjustments in presenting Adjusted Diluted Earnings per Share, when used in conjunction with diluted earnings per share, are appropriate to provide additional information to investors, reflects more accurately operating results of the on-going operations, enhances the overall understanding of past financial performance and future prospects and allows for greater transparency with respect to the key metrics the Company uses in its financial and operational decision making. The Company also believes that Adjusted Diluted Earnings per Share is frequently used by securities analysts, investors and other interested parties in the evaluation of companies in its industry. Adjusted Diluted Earnings per Share may not be comparable to other similarly titled captions of other companies due to differences in the non-GAAP calculation.

The following unaudited tables below provide a reconciliation of Adjusted Diluted Earnings Per Share to its most directly comparable GAAP measure, which is diluted earnings per share, for the thirteen and twenty-six weeks ended February 27, 2021 and February 29, 2020:

    Thirteen Weeks Ended   Twenty-Six Weeks Ended
    February 27, 2021   February 29, 2020   February 27, 2021   February 29, 2020
Diluted earnings per share   $ 0.19     $ 0.11     $ 0.41     $ 0.06  
                 
Depreciation and amortization   0.04     0.05     0.09     0.07  
Business transaction costs       0.01         0.28  
Stock-based compensation expense   0.02     0.02     0.04     0.04  
Inventory step-up       0.05         0.08  
Integration of Quest   0.01     0.04     0.02     0.05  
Restructuring   0.01         0.04      
Non-core legal costs               0.01  
Other (1)   (0.01 )       (0.01 )    
Tax effects of adjustments (2)   (0.02 )   (0.04 )   (0.05 )   (0.14 )
Rounding (3)   0.01     (0.01 )        
Adjusted diluted earnings per share   $ 0.25     $ 0.23     $ 0.54     $ 0.45  

(1) Other items consist principally of exchange impact of foreign currency transactions and other expenses.
(2) This line item reflects the aggregate tax effect of all non-tax adjustments reflected in the preceding line items of the table. The tax effect of each adjustment is computed (i) by dividing the gross amount of the adjustment, as shown in the Adjusted EBITDA reconciliation, by the number of diluted weighted average shares outstanding for the applicable fiscal period and (ii) applying an overall assumed statutory tax rate of 27% for the thirteen and twenty-six weeks ended February 27, 2021 and 26% for the thirteen and twenty-six weeks ended February 29, 2020.
(3) Adjusted Diluted Earnings Per Share amounts are computed independently for each quarter. Therefore, the sum of the quarterly Adjusted Diluted Earnings Per Share amounts may not equal the year to date Adjusted Diluted Earnings Per Share amounts due to rounding.


Reconciliation of Net Debt to Adjusted EBITDA


Net Debt to Adjusted EBITDA
. Net Debt to Adjusted EBITDA is a non-GAAP financial measure which Simply Good Foods defines as the total debt outstanding under our credit agreement with Barclays Bank PLC and other parties (“Credit Agreement”), reduced by cash and cash equivalents, and divided by the trailing twelve months of Adjusted EBITDA, as previously defined.

The following unaudited table below provides a reconciliation of Net Debt to Adjusted EBITDA as of February 27, 2021:

(In thousands)   February 27, 2021
Net Debt:    
Total debt outstanding under the Credit Agreement   $ 556,500  
Less: cash and cash equivalents   (91,307 )
Net Debt as of February 27, 2021   $ 465,193  
     
Trailing twelve months Adjusted EBITDA:    
Add: Adjusted EBITDA for the thirteen weeks ended February 27, 2021   $ 91,341  
Add: Adjusted EBITDA for the fiscal year ended August 29, 2020   153,912  
Less: Adjusted EBITDA for the thirteen weeks ended February 29, 2020   (73,526 )
Trailing twelve months Adjusted EBITDA as of February 27, 2021   $ 171,727  
     
Net Debt to Adjusted EBITDA   2.7 x



BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., April 07, 2021 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 8:45 a.m. ET.

Links to a live audio webcast and replay of this presentation may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States and Japan for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in the European Union and United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW


Contact:


Investors

John Bluth
+1 919 859 7910
[email protected]

Media

Catherine Collier Kyroulis
+1 917 886 5586
[email protected] 



Versus Systems to Allow Prizing in UK Starting in Q2

Adding Europe’s Largest TV Advertising Market Significantly Expands the Reach of Versus’ Prizing Technology

LOS ANGELES, April 07, 2021 (GLOBE NEWSWIRE) — Versus Systems Inc. (“Versus” or the “Company”) (Nasdaq: VS) (FRANKFURT: BMVB) today announced that it has added new functionality to its patented Dynamic Regulatory Compliance prizing engine to support uses in the United Kingdom, which is the largest television advertising market in Europe, one of the largest interactive gaming markets in the world, and home to the Premier League, the most popular football league in the world. Versus will be partnering with some of its existing content partners to launch in the UK in Q2 of this year.

With a population of over 66 million1, the UK is a global leader in media consumption with 37 million people playing video games2, approximately 20 million subscribers to OTT and streaming services3, and an average of 1.5 million viewers tuning in to each of the 380 Premier League season games in 2018/20194.

By expanding into the UK market, Versus will leverage its gaming and second-screen expertise to provide unique prizing solutions for brands and content partners looking to engage with this audience across multiple screens and live events.

“The UK’s deep penetration of gaming, interactive TV, and streaming services represent tremendous opportunities for content creators and brands that want to add prizing and interactive engagement for their audiences,” said Matthew Pierce, Versus’ CEO. “Adding access to UK is a very natural target for expansion, given our multi-year partnerships with Xcite, Frias, HP, and all of our content and brand partners.”

____________

1 Statista, Total population of the United Kingdom (UK) from 2015 to 2025, 2019-2020
2 The Creative Industries Council, 2018
3 Statista, Estimated number of unique subscribers to OTT SVOD services in Europe in 2018, by country, 2018
4 TopMedia, 2020


About Versus Systems

Versus Systems Inc. has developed a proprietary in-game prizing and promotions engine that allows publishers, developers, and creators of games, apps, and other interactive media content to offer real world prizes inside their content. Players, viewers and users can choose from among the offered prizes and then complete in-game or in-app challenges to win the prizes. The Versus platform can be integrated into mobile, console, and PC games, as well as streaming media and mobile apps. For more information, please visit www.versussystems.com or visit the official Versus Systems YouTube channel.

Investor contact:

Sean McGowan, Cody Slach
Gateway Investor Relations
949-574-3860
[email protected]
or
[email protected]


Disclaimer for Forward-Looking Information 

This news release contains certain forward-looking information and forward-looking statements within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward looking statements. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking statements and information. There can be no assurance that forward-looking information, or the material factors or assumptions used to develop such forward-looking information, will prove to be accurate. The Company does not undertake any obligations to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable law. 



Skylight Health Announces Partnership with ClinEdge for Clinical Trials in the US


Skylight Health signs partnership with ClinEdge to bring clinical research to primary care practices in Massachusetts

  • ClinEdge has over ten years experience partnering prominent research sponsors with clinical research sites;
  • Skylight Health provides primary care services in multiple states across the US, and will act as a clinical research site partner for ClinEdge;
  • The partnership with ClinEdge will bring industry-sponsored trials to Skylight Health’s clinics beginning with Massachusetts to accelerate growth in the field of research; and
  • This partnership demonstrates the value of Skylight’s diversity in healthcare services across the United States.

TORONTO, April 07, 2021 (GLOBE NEWSWIRE) — Skylight Health Group Inc (TSXV:SHG; OTCQX: SHGFF) (“Skylight Health” or the “Company”), a multi-state primary care management group in the United States, announced today a partnership with ClinEdge, one of North America’s leading clinical research groups.

ClinEdge provides a full suite of services to support clinical research institutions, Contract Research Organizations (“CROs”), and sponsors. Their mission is to develop and grow service lines that positively affect the cost structure, timeliness and accuracy of administering clinical research. Their relationships with CROs and other industry sponsors ensure the success of their Study Lead Generation Services to identify clinical trials to suit the population of each research site in their network. ClinEdge works closely with clinical research sites to ensure their success in being awarded clinical research trials from highly experienced and well-known industry sponsors.

“Partnering with sponsors that share a similar vision on the importance of quality clinical research that puts patients first is vital to Skylight’s growth and the growth of the US healthcare system at-large,” said Alisha Garibaldi, Clinical Research Manager, Skylight Health Group. “ClinEdge brings unparalleled experience in this field, and we’re proud to have solidified this partnership.”

This partnership with ClinEdge will add to the 50+ years of experience on the Skylight Health Research Team and will bring clinical research trials investigating a wide range of indications beginning with the clinical sites in Massachusetts. This will provide an opportunity for patients in Massachusetts to participate in these trials, which may provide them access to new therapies, treatments or vaccines. Skylight Health understands the value of research, and not only wants to provide the best care of their own patients but wants to ensure that as a Company, they can contribute to the broader medical science community as it continues to progress. Based on the success in Massachusetts, Skylight will look to further expand this partnership across other US states.

ClinEdge brings trials opportunities in a wide range of indications, including diabetes, COVID-19, arthritis, post-traumatic stress disorder, hypertension, and many others. Patient participation in trials awarded to Skylight Health will be available for both existing patients, as well as individuals who may not be patients of Skylight Health but are interested in contributing to clinical research.

Apart from being able to contribute to scientific knowledge, participating in clinical research trials can financially benefit Skylight Health and patients alike. The award for clinical research sites may range from $1,000 – $15,000 per patient per trial, and patients receive stipends to compensate for their time and effort for participating in clinical trials as well as reimbursements for expenses incurred. The teams at ClinEdge and Skylight carefully screen all trials for scientific and ethic rigour prior to reaching out to potential patients.

“At Skylight Health we focus on continually improving the care of our patients through research, data, and innovation. We are excited to announce our partnership with ClinEdge as it is the next step in the expansion of our clinical research program. This partnership represents an opportunity for our clinics and patients to make meaningful contributions to the improvement of healthcare through clinical research while providing access to new therapies and the potential for subsidized care,” Christopher Smith, SVP of Digital Health and Research, Skylight Health.

About Skylight Health Group

Skylight Health Group (TSXV:SHG; OTCQX:SHGFF) is a healthcare services and technology company, working to positively impact patient health outcomes. The Company operates a US multi-state health network that comprises of physical multi-disciplinary medical clinics providing a range of services from primary care, sub-specialty, allied health and laboratory/diagnostic testing. The Company owns and operates a proprietary electronic health record system that supports the delivery of care to patients via telemedicine and other remote monitoring system integrations. With a patient roster of over 155,000 patients, the Company’s operations servicing 16 states and continues to expand in services and locations both organically and by way of strategic acquisitions.

The Company primarily operates a traditional insurable fee-for-service model contracting with Medicare, Medicaid and other Commercial Payors. The Company also offers a disruptive subscription-based telemedicine service for the un/under-insured population who have limited access to urgent care due to cost.

About ClinEdge

ClinEdge provides a full suite of clinical trial management solutions to pharmaceutical companies, CROs, and clinical research sites. Offerings include a global site network of research clinics, patient recruitment and retention, marketing and creative design, patient travel coordination, clinical trial management, staffing, and financial management.  With extensive experience in multiple medical indications representing all therapeutic areas, including a specialty in rare disease engagement, ClinEdge has helped clients successfully conduct thousands of clinical studies by boosting patient recruitment, minimizing enrollment times, driving retention, and improving overall business performance.

For more information visit www.clin-edge.com.

For more information on Skylight Health Group or this announcement, please visit www.skylighthealthgroup.com or contact:

Investor Relations:

Jackie Kelly
[email protected]
416-301-2949

Currency Usage, Cautionary and Forward-Looking Statements

All currency contained in this Press Release represent Canadian Dollars unless otherwise stated.

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Skylight Health’s filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements regarding the Company’s unaudited financial results and projected growth.

Financial forecasts in this release are based on the current revenue run rate of Skylight Health, all of its recently completed acquisitions, and its pending acquisitions. This forecast is subject to the closing of any and all pending acquisitions, and successful integration of all its current and future acquisitions without any loss or interruptions of revenues during the integration and transition process. The Company may revise this forecast from time to time and investors should not solely rely on this forward-looking guidance when making an investment decision.

Although Skylight Health has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: the ability of Skylight Health to execute on its business strategy, continued revenue growth in accordance with management’s expectations, operating expenses continuing in accordance with management expectations, dependence on obtaining regulatory approvals; Skylight Health being able to find, complete and effectively integrate target acquisitions; change in laws relating to health care regulation; reliance on management; requirements for additional financing; competition; hindering market growth or other factors that may not currently be known by the Company.

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Skylight Health disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Skylight Health does not assume any liability for disclosure relating to any other company mentioned herein.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 



G1 Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., April 07, 2021 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will participate in the 20th Annual Needham Virtual Healthcare Conference. The fireside chat will take place on April 14th at 12:45 PM EDT. This meeting is being held virtually, and a live webcast will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.

About G1 Therapeutics

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product COSELA™ (trilaciclib). G1 has a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Contacts:

Will Roberts
Vice President, Investor Relations & Corporate Communications
919-907-1944
[email protected]



XPO Logistics Accelerates Hiring to Support Growth of Less-Than-Truckload Business in North America

Over 1,400 CDL-A driver and dockworker positions available

GREENWICH, Conn., April 07, 2021 (GLOBE NEWSWIRE) —  

XPO Logistics, Inc.
(NYSE: XPO), a leading global provider of transportation and logistics services, today announced a new wave of hiring initiatives for its less-than-truckload (LTL) business. The company is recruiting for more than 1,400 positions across North America to meet growing demand for its LTL services, as the economy rebounds from COVID-19.

Approximately 750 CDL-A commercial truck driver jobs and 700 dockworker jobs are currently available, including 100 openings for candidates who want to earn pay as a dockworker while training tuition-free for a commercial driving career at XPO. Applicants can search all open positions by location and keyword on XPO’s Careers site, and apply online.

XPO is one of the largest LTL providers in North America, with 290 service centers and coast-to-coast digital visibility into more than 17 billion pounds of freight picked up and delivered by its drivers each year. The company is seeing increased LTL activity from several sources, including an improvement in the industrial economy and the rapid growth of e-commerce, which is driving more retail shipments to LTL carriers.

Josephine Berisha, chief human resources officer of XPO Logistics, said, “We’re proud that our LTL operations are a strong source of jobs creation, and that our customers will have this additional support. We look forward to welcoming over 1,400 new team members – and more after that as the year progresses.”    

The company offers qualified applicants a strong total compensation package that includes:

  • Competitive pay and benefits, with benefits starting on day one of employment
  • Training and technology that enhances job satisfaction
  • A safe, inclusive and supportive workplace
  • An accelerated path for hourly workers to reach top pay rate, merit increases, performance rewards and flexible shifts
  • The potential for dockworkers to train tuition-free for a CDL-A license
  • Tuition reimbursement for recent CDL-A driver school graduates
  • The ability to explore career paths within the company

XPO recently honored 230 of its LTL drivers for accident-free achievements of one, two or three million miles in 2020. The company tracks LTL performance as part of its Road to Zero safety program. On average, it takes a driver approximately a decade of safe driving to achieve one million miles without an accident.

About XPO Logistics

XPO Logistics, Inc. (NYSE: XPO) provides cutting-edge supply chain solutions to the most successful companies in the world. The company is the second largest contract logistics provider and the second largest freight broker globally, and a top three less-than-truckload provider in North America. XPO uses a highly integrated network of 1,629 locations and over 100,000 employees in 30 countries to help more than 50,000 customers manage their supply chains most efficiently. The company’s corporate headquarters are in Greenwich, Conn., USA, and its European headquarters are in Lyon, France. Visit xpo.com for more information, and connect with XPO on Facebook, Twitter, LinkedIn, Instagram and YouTube.

Media Contact

XPO Logistics, Inc.
Joe Checkler
+1-203-423-2098
[email protected]